Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026
Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.
We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar.
WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.
Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.
In this webinar, get a comprehensive overview of the UK’s biotech and life sciences presence at BIO 2025. Learn about the UK delegation’s plans, including the UK Pavilion organised by the Department for Business and Trade.
BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.
Symbiosis, a global biopharmaceutical CMO specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category.
President Trump’s “Liberation Day” announcement on April 2 could disrupt biotech, with BIO’s survey showing 90% of U.S. biotech firms relying on imports for FDA-approved products. In addition, news from the mRNA vaccine progress, new lab spaces and Innovate UK’s new leadership.
University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.
Nxera Pharma reports significant progress on its partnered muscarinic agonist portfolio with Neurocrine Biosciences, including plans for Phase 3 schizophrenia trials and multiple Phase 2 studies in 2025.
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding its innovative schizophrenia and bipolar treatment CAPLYTA® to J&J's neuroscience portfolio, along with a promising pipeline of therapies.
A new biotech venture is advancing best-in-class oral and injectable therapies for obesity and cardiometabolic disorders, backed by $411 million in funding from leading global investors.
GSK has announced the acquisition of IDRX-42, a next-generation KIT tyrosine kinase inhibitor (TKI). This $1.15 billion deal strengthens GSK’s portfolio in gastrointestinal cancers.
